Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Pellegrini, Cristina; Esposito, Maria; Rossi, Ernesto; Gisondi, Paolo; Piaserico, Stefano; Dapavo, Paolo; Conti, Andrea A.; Gambardella, Alessio; Burlando, Martina; Narcisi, Alessandra; Offidani, Annamaria; Balestri, Riccardo; Bardazzi, Federico; Prignano, Francesca; Mugheddu, Cristina; Romanelli, Marco; Malara, Giovanna; Schinzari, Giovanni; Fargnoli, Maria Concetta

doi:10.1007/s13555-022-00797-9

Cited by 21 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding on the efficacy in bio-naïve subjects assessed by absolut-PASI ≤3, and drug survival, our results are similar to those obtained in previous reports, and slightly higher to those obtained in clinical trials, but our mean follow-up period is longer. 1,7,[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Furthermore, in our study both secukinumab response and drug survival in non-biologic-experienced patients were found to be independent of weight, age, sex and the presence of psoriatic arthritis, in contrast with some previously reported series 11,14,18,19 which also included biologicalexperienced subjects, what could explain these facts. We wanted to highlight the low incidence of psoriatic arthritis (18.8%), diabetes (14.8%) and cardiac failure (3.9%) in our study.…”

Section: Discussioncontrasting

confidence: 99%

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Ramos

Puchades

Climent

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundThere is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early intensive treatment with biological therapies could decrease pathogenic tissue resident memory (TRm) cells migration and potentially modify the natural course of psoriasis and related comorbidities.ObjectivesTo analyze long‐term secukinumab efficacy, safety and survival, and its predictive factors for psoriasis treatment determining also whether early intervention may result in better outcomes for patients.MethodsBio‐naïve psoriatic patients under treatment with secukinumab (n = 128 patients) in a daily practice setting were analyzed in a retrospective multicentric study and followed up to 8 years. Drug survival rate, efficacy, posology and safety were reported.ResultsThe overall secukinumab survival was 81.9% for an average treatment exposure of 147.9 weeks. The approved posology was the most commonly prescribed regimen (78.7%), and 17.7% could be optimized. An absolut‐PASI ≤3 was reached by 86.6%, 82.6% and 91.7% at the weeks 48,156 and 264, respectively. The incidence of arthritis or psoriasis related comorbidities was low. The response was not influenced by weight, age (>65), gender or the presence of arthritis. No severe adverse events were reported.ConclusionsIn our bio‐naïve series, the high efficacy and long‐term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed.

show abstract

Section: Discussioncontrasting

confidence: 99%

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Ramos

Puchades

Climent

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Recently, some case series have been reported about RDM patients treated with biologics without experiencing relapses. [4][5][6][7] Our results, describing the largest population treated with biologics having RDM with the longest follow-up time (38.06 months), are in line with previous findings. Moreover, compared to the group that started a biologic after 5 years from diagnosis, no statistically significant differences were observed regarding relapses (p-value = 0.66) over a similar follow-up period.…”

supporting

confidence: 92%

Biologics in psoriatic patients with malignancies: Where are we now? An Italian multicentric study

Magnano,

Balestri,

Gisondi

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…Rare reasons for discontinuation are death, cancer, pregnancy and migration. Since those reasons are rare and because we censored treatment series on the occurrence of those for all groups, it will likely not have had a large impact on the results 27,28 .…”

Section: Discussionmentioning

confidence: 99%

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

Nielsen,

Petersen,

Maul

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundSome patients treated with biologic therapy for psoriasis experience adverse events causing treatment discontinuation.ObjectivesTo identify predictors of adverse events resulting in discontinuation of biologics for psoriasis.MethodsThis cohort study involved data from the Danish nationwide registry DERMBIO. A classification algorithm based on gradient‐boosted decision trees combined with a mixed‐effects model was applied to data on various drugs to predict treatment discontinuation caused by adverse events and to identify important predictors.ResultsThis study comprised 4876 treatment series, including 3078 (63.1%) that were discontinued. With adverse events causing 19.6% of these, it was the second most frequent reason for discontinuation following ineffectiveness. The proportion of treatments discontinued due to adverse events was 20.0% [16.7%, 23.9%; 95% confidence interval (CI)] among patients that had discontinued their previous treatment series due to adverse events, and 11.6% [10.3%, 13.1%; 95% CI] among treatment series where the previous treatment was discontinued due to other reasons (p < 0.001).ConclusionsThe proportion of treatment series discontinued due to adverse events among patients who had discontinued their previous treatment due to adverse events was 72.4% larger compared to those who discontinued their previous treatment for other reasons.

show abstract

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

Cited by 21 publications

References 30 publications

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Biologics in psoriatic patients with malignancies: Where are we now? An Italian multicentric study

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study

Contact Info

Product

Resources

About